MX2018011696A - Composición farmacéutica de dapagliflozina. - Google Patents
Composición farmacéutica de dapagliflozina.Info
- Publication number
- MX2018011696A MX2018011696A MX2018011696A MX2018011696A MX2018011696A MX 2018011696 A MX2018011696 A MX 2018011696A MX 2018011696 A MX2018011696 A MX 2018011696A MX 2018011696 A MX2018011696 A MX 2018011696A MX 2018011696 A MX2018011696 A MX 2018011696A
- Authority
- MX
- Mexico
- Prior art keywords
- dapagliflozin
- pharmaceutical composition
- stable pharmaceutical
- premix
- discloses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención divulga una composición farmacéutica estable conformada por una premezcla de dapagliflozina con al menos un excipiente o excipientes farmacéuticamente aceptables, así como el proceso para su elaboración. La dapagliflozina es altamente higroscópica y, por lo tanto, es difícil formularla como una composición farmacéutica estable. La presente invención divulga una composición farmacéutica estable de dapagliflozina que comprende una premezcla de dapagliflozina con lactosa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201621011351 | 2016-03-31 | ||
PCT/IB2017/051823 WO2017168360A1 (en) | 2016-03-31 | 2017-03-30 | Pharmaceutical composition of dapagliflozin |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018011696A true MX2018011696A (es) | 2019-06-06 |
Family
ID=58549178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018011696A MX2018011696A (es) | 2016-03-31 | 2017-03-30 | Composición farmacéutica de dapagliflozina. |
Country Status (8)
Country | Link |
---|---|
US (1) | US20190110994A1 (es) |
EP (1) | EP3435987A1 (es) |
JP (1) | JP2019512537A (es) |
BR (1) | BR112018069782A2 (es) |
MX (1) | MX2018011696A (es) |
PH (1) | PH12018502089A1 (es) |
WO (1) | WO2017168360A1 (es) |
ZA (1) | ZA201807125B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11020412B2 (en) | 2017-03-16 | 2021-06-01 | Inventia Healthcare Limited | Pharmaceutical composition comprising dapagliflozin |
US20230033410A1 (en) * | 2019-12-24 | 2023-02-02 | Hanmi Pharm. Co.,Ltd. | Complex formulation comprising sitagliptin and dapagliflozin, and preparation method therefor |
TR202004809A2 (tr) * | 2020-03-27 | 2021-10-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Metformi̇n ve dapagli̇flozi̇n i̇çeren bi̇r saşe formülasyonu |
WO2022119543A1 (en) * | 2020-12-03 | 2022-06-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A process for tablet formulations comprising amorphous dapagliflozin and metformin hydrochloride |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
SI2498758T1 (sl) * | 2009-11-13 | 2018-10-30 | Astrazeneca Ab | Formulacije dvoplastnih tablet |
JP5837072B2 (ja) * | 2010-09-03 | 2015-12-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 水溶性抗酸化剤を使用する製剤 |
CA2837232A1 (en) | 2011-06-03 | 2012-12-06 | Ratiopharm Gmbh | Pharmaceutical composition comprising dapagliflozin and cyclodextrin |
WO2014178040A1 (en) * | 2013-04-29 | 2014-11-06 | Mapi Pharma Ltd. | Co-crystals of dapagliflozin |
WO2015128853A1 (en) * | 2014-02-28 | 2015-09-03 | Sun Pharmaceutical Industries Limited | Dapagliflozin compositions |
-
2017
- 2017-03-30 BR BR112018069782A patent/BR112018069782A2/pt not_active Application Discontinuation
- 2017-03-30 JP JP2018551765A patent/JP2019512537A/ja active Pending
- 2017-03-30 WO PCT/IB2017/051823 patent/WO2017168360A1/en active Application Filing
- 2017-03-30 US US16/089,898 patent/US20190110994A1/en not_active Abandoned
- 2017-03-30 MX MX2018011696A patent/MX2018011696A/es unknown
- 2017-03-30 EP EP17718128.6A patent/EP3435987A1/en not_active Withdrawn
-
2018
- 2018-09-28 PH PH12018502089A patent/PH12018502089A1/en unknown
- 2018-10-25 ZA ZA2018/07125A patent/ZA201807125B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201807125B (en) | 2019-08-28 |
WO2017168360A1 (en) | 2017-10-05 |
BR112018069782A2 (pt) | 2019-01-29 |
US20190110994A1 (en) | 2019-04-18 |
PH12018502089A1 (en) | 2019-07-15 |
JP2019512537A (ja) | 2019-05-16 |
EP3435987A1 (en) | 2019-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018502251A1 (en) | Formulations of an lsd1 inhibitor | |
PH12017500281A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
PH12018502089A1 (en) | Pharmaceutical composition of dapagliflozin | |
PH12016501355A1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
MA40539A (fr) | Procédés de formulation de compositions de conjugués anticorps-médicaments | |
IN2013MU03583A (es) | ||
IN2014MN02236A (es) | ||
MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
MX2019004580A (es) | Formulaciones farmaceuticas y metodos para prepararlas. | |
MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
MX2017009289A (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas. | |
EA201890944A1 (ru) | Фармацевтические композиции нилотиниба гидрохлорида | |
TR201722603A2 (tr) | Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari | |
MX2021007032A (es) | Derivados activos de éster de testosterona, composiciones y usos de los mismos. | |
MX2021015441A (es) | Formas cristalinas de cabotegravir de sodio. | |
WO2017021974A3 (en) | NOVEL SYNERGISTIC COMPOSITION OF LECITHIN AND LYSOLECHINE TO IMPROVE BIOAVAILABILITY AND SOLUBILITY OF HYDROPHOBIC COMPOUNDS AND EXTRACTS | |
WO2018119108A8 (en) | Solid pharmaceutical formulations of asimadoline | |
TR201714882A2 (tr) | Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari | |
WO2016197042A8 (en) | Modified or targeted release formulations of linaclotide | |
NZ728660A (en) | A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor | |
PH12020500045A1 (en) | Novel composition of enzalutamide oral dosage form and method of manufacturing thereof | |
IN2013MU01868A (es) | ||
AU2017260751A1 (en) | Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine |